

- 1 **Supplementary Table S8.** Summary of best overall response of patients treated with
- 2 botensilimab monotherapy or botensilimab in combination with balstilimab.

Patient ID	Treatment	Cancer Type	Prior α PD-1(L1)	Prior α CTLA-4	Best overall response
1	Botensilimab Monotherapy: 1.0 mg/kg Q3W	MSS Colorectal cancer (CRC)	No	No	SD
2			No	No	PD
3			Yes	No	SD
4			No	No	PD
5			No	No	SD
6			No	No	PD
7			No	No	PD
8			Yes	No	SD
9			No	No	PD
10			No	No	PD
11			No	No	SD
12			No	No	SD
13			No	No	PD
14			Yes	No	PD
15			Yes	No	SD
16			No	No	SD
17	Botensilimab Monotherapy: 1.0 mg/kg Q6W		No	No	SD
18	Botensilimab Monotherapy: 2.0 mg/kg Q6W		No	No	PD

19	Botensilimab Monotherapy: 0.3 mg/kg Q3W	MSS Colorectal cancer (CRC)	Yes	No	PD
20	Botensilimab 1.0 mg/kg Q6W + Balstilimab 3.0 mg/kg Q2W		No	No	SD
21			No	No	SD
22			Yes	No	SD
23			No	No	PD
24			Yes	No	PD
25			No	No	SD
26			No	No	SD
27			No	No	NA
28			No	No	PD
29			Yes	No	PD
30			Yes	No	PR
31			No	No	SD
32			No	No	PR
33			No	No	PD

34	Botensilimab 1.0 mg/kg Q6W + Balstilimab 3.0 mg/kg Q2W	MSS Colorectal cancer (CRC)	No	No	SD
35			Yes	No	PD
36			No	No	SD
37			No	No	SD
38			No	No	SD
39			No	No	NA
40			No	No	SD
41			No	No	SD
42			No	No	SD
43	Botensilimab 150 mg Q6W + Balstilimab 450 mg Q3W		No	No	PD
44	Botensilimab 2.0 mg/kg Q6W + Balstilimab 3.0 mg/kg Q2W		No	No	PD
45		No	No	PD	
46		No	No	PR	
47		No	No	CR	

48	Botensilimab 2.0 mg/kg Q6W + Balstilimab 3.0 mg/kg Q2W	MSS Colorectal cancer (CRC)	No	No	SD
49			Yes	No	PD
50			No	No	PD
51			Yes	No	SD
52			Yes	No	SD
53			No	No	SD
54			No	No	PD
55			No	No	PD
56			No	No	SD
57			No	No	PD
58			No	No	PD
59			No	No	PD
60			No	No	PD
61			No	No	SD

62	Botensilimab 2.0 mg/kg Q6W + Balstilimab 3.0 mg/kg Q2W	MSS Colorectal cancer (CRC)	No	No	SD
63			No	No	NE
64			No	No	SD
65			No	No	SD
66			No	No	SD
67			Yes	No	SD
68			No	No	SD
69			No	No	PR
70			No	No	PR
71			Yes	No	SD
72			No	No	PR
73			No	No	SD
74			No	No	PD
75			Yes	No	SD

76	Botensilimab 2.0 mg/kg Q6W + Balstilimab 3.0 mg/kg Q2W	MSS Colorectal cancer (CRC)	Yes	No	PD
77			Yes	No	SD
78			No	No	PR
79			Yes	No	PD
80			No	No	PD
81			Yes	No	SD
82			Yes	No	SD
83			No	No	PD
84			No	No	PD
85			No	No	PD
86			No	No	SD
87			Yes	No	SD
88			No	No	NA
89			No	No	PR

90	Botensilimab 2.0 mg/kg Q6W + Balstilimab 3.0 mg/kg Q2W	MSS Colorectal cancer (CRC)	No	No	SD
91			No	No	SD
92			Yes	Yes	SD
93			No	No	PD
94			No	No	PR
95			No	No	PD
96			No	No	PD
97	Botensilimab Monotherapy: 0.1 mg/kg Q3W	Ovarian Cancer	Yes	No	SD
98	Botensilimab Monotherapy: 0.3 mg/kg Q3W		Yes	No	SD
99	Botensilimab Monotherapy: 1.0 mg/kg Q3W		Yes	No	SD
100	Botensilimab 0.1 mg/kg Q6W + Balstilimab 3.0 mg/kg Q2W		No	No	PD
101			No	No	SD
102	Botensilimab 1.0 mg/kg Q6W + Balstilimab 3.0 mg/kg Q2W		No	No	SD
103			No	No	PD
104		No	No	PR	

105	Botensilimab 1.0 mg/kg Q6W + Balstilimab 3.0 mg/kg Q2W	Ovarian Cancer	No	No	SD
106			Yes	No	PR
107	Botensilimab 150 mg Q6W + Balstilimab 450 mg Q3W		No	No	NA
108			No	No	SD
109	Botensilimab 2.0 mg/kg Q6W + Balstilimab 3.0 mg/kg Q2W		No	No	SD
110			No	No	SD
111			No	No	PR
112			No	No	SD
113			No	No	PD
114			No	No	PR
115			No	No	PD
116			No	No	PD
117			No	No	PR
118			No	No	PD

119	Botensilimab 2.0 mg/kg Q6W + Balstilimab 3.0 mg/kg Q2W	Ovarian Cancer	No	No	PD
120			No	No	PD
121			No	No	PD
122			No	No	PD
123	Botensilimab Monotherapy: 2.0 mg/kg Q3W	Sarcoma	No	No	PD
124			No	No	PD
125	Botensilimab Monotherapy: 3.0 mg/kg Q3W		Yes	Yes	PD
126	Botensilimab 1.0 mg/kg Q6W + Balstilimab 3.0 mg/kg Q2W		No	No	PR
127			No	No	PD
128			No	No	PD
129			No	No	SD
130			No	No	SD
131			No	No	SD
132			No	No	PD
133		No	No	SD	

134	Botensilimab 1.0 mg/kg Q6W + Balstilimab 3.0 mg/kg Q2W	Sarcoma	No	No	SD	
135			No	No	PD	
136			Botensilimab 2.0 mg/kg Q6W + Balstilimab 3.0 mg/kg Q2W	No	No	PD
137				No	No	PD
138	Botensilimab Monotherapy: 1.0 mg/kg Q3W	Pancreatic cancer	No	No	PD	
139	Botensilimab Monotherapy: 2.0 mg/kg Q3W		No	No	NA	
140			No	No	PD	
141	Botensilimab Monotherapy: 3.0 mg/kg Q3W		No	No	PD	
142	Botensilimab 2.0 mg/kg Q6W + Balstilimab 3.0 mg/kg Q2W		No	No	PD	
143			No	No	PD	
144			No	No	PD	
145			No	No	PD	
146			Yes	No	PD	
147	Botensilimab 150 mg Q6W + Balstilimab 450 mg Q3W		No	No	PD	
148	Botensilimab 1.0 mg/kg Q6W + Balstilimab 3.0 mg/kg Q2W	Angiosarcoma	No	No	PD	

149	Botensilimab 2.0 mg/kg Q6W + Balstilimab 3.0 mg/kg Q2W	Angiosarcoma	No	No	PR
150			No	No	PR
151			No	No	SD
152			No	No	PD
153			Yes	No	PD
154			No	No	PR
155			No	No	SD
156			Yes	No	SD
157	Botensilimab Monotherapy: 0.1 mg/kg Q3W	Melanoma	Yes	No	SD
158	Botensilimab Monotherapy: 2.0 mg/kg Q3W		Yes	No	NA
159			Yes	Yes	PD
160			Yes	Yes	PD
161			Yes	Yes	SD
162			Yes	No	PR
163			Yes	Yes	PR
164	Botensilimab Monotherapy: 3.0 mg/kg Q3W		Yes	No	PD
165	Botensilimab 1.0 mg/kg Q6W + Balstilimab 3.0 mg/kg Q2W	Yes	Yes	PR	

166	Botensilimab Monotherapy: 1.0 mg/kg Q6W	Renal cell carcinoma	Yes	No	PD
167	Botensilimab Monotherapy: 1.0 mg/kg Q3W		Yes	No	PD
168	Botensilimab Monotherapy: 2.0 mg/kg Q6W		No	No	SD
169	Botensilimab Monotherapy: 2.0 mg/kg Q3W		No	No	SD
170			Yes	No	PD
171	Botensilimab Monotherapy: 1.0 mg/kg Q3W	Ampullary of Vater carcinoma	No	No	PD
172			No	No	SD
173	Botensilimab Monotherapy: 2.0 mg/kg Q6W		No	No	SD
174	Botensilimab Monotherapy: 3.0 mg/kg Q3W		No	No	PD
175	Botensilimab 2.0 mg/kg Q6W + Balstilimab 3.0 mg/kg Q2W	Hepatocellular carcinoma	Yes	No	PD
176			Yes	No	SD
177			Yes	No	SD
178			Yes	No	PD
179	Botensilimab Monotherapy: 0.3 mg/kg Q3W	Non-Small Cell Lung Cancer (NSCLC)	Yes	No	SD
180	Botensilimab 2.0 mg/kg Q6W + Balstilimab 3.0 mg/kg Q2W		Yes	No	PR
181			Yes	No	PR

182	Botensilimab 150 mg Q6W + Balstilimab 450 mg Q3W	Non-Small Cell Lung Cancer (NSCLC)	Yes	No	PR
183	Botensilimab Monotherapy: 2.0 mg/kg Q3W	Breast cancer	No	No	PD
184	Botensilimab 0.3 mg/kg Q6W + Balstilimab 3.0 mg/kg Q2W		No	No	PD
185	Botensilimab 2.0 mg/kg Q6W + Balstilimab 3.0 mg/kg Q2W		No	No	PD
186	Botensilimab Monotherapy: 1.0 mg/kg Q3W	Endometrial Carcinoma	Yes	No	CR
187	Botensilimab 0.1 mg/kg Q6W + Balstilimab 3.0 mg/kg Q2W		No	No	PR
188	Botensilimab 1.0 mg/kg Q6W + Balstilimab 3.0 mg/kg Q2W		Yes	No	PD
189	Botensilimab Monotherapy: 0.1 mg/kg Q3W	Head and Neck cancer	Yes	No	NA
190	Botensilimab Monotherapy: 2.0 mg/kg Q3W		Yes	No	PD
191	Botensilimab Monotherapy: 2.0 mg/kg Q6W		Yes	No	PD
192	Botensilimab Monotherapy: 3.0 mg/kg Q3W	Anal cancer	Yes	No	SD
193	Botensilimab 1.0 mg/kg Q6W + Balstilimab 3.0 mg/kg Q2W		No	No	PD
194	Botensilimab Monotherapy: 2.0 mg/kg Q3W	Cervical cancer	Yes	No	PD
195	Botensilimab Monotherapy: 3.0 mg/kg Q3W		Yes	No	PR
196	Botensilimab Monotherapy: 0.3 mg/kg Q3W	Esophageal cancer	No	No	SD
197	Botensilimab Monotherapy: 2.0 mg/kg Q6W		No	No	PD

198	Botensilimab Monotherapy: 1.0 mg/kg Q3W	Prostate cancer	No	No	PD
199	Botensilimab Monotherapy: 2.0 mg/kg Q6W		No	No	SD
200	Botensilimab Monotherapy: 2.0 mg/kg Q3W	Thyroid carcinoma	No	No	PD
201	Botensilimab 0.3 mg/kg Q6W + Balstilimab 3.0 mg/kg Q2W		No	No	PD
202	Botensilimab 1.0 mg/kg Q6W + Balstilimab 3.0 mg/kg Q2W	Undetermin ed carcinoma	No	No	PD
203			Yes	No	SD
204	Botensilimab 1.0 mg/kg Q6W + Balstilimab 3.0 mg/kg Q2W	Adrenocorti cal carcinoma	No	No	SD
205	Botensilimab Monotherapy: 2.0 mg/kg Q3W	Cholangioc arcinoma	No	No	SD
206	Botensilimab 150 mg Q6W + Balstilimab 450 mg Q3W	Fibrolamella r carcinoma	Yes	No	SD
207	Botensilimab Monotherapy: 0.3 mg/kg Q3W	Gallbladder cancer	No	No	NA
208	Botensilimab 2.0 mg/kg Q6W + Balstilimab 3.0 mg/kg Q2W	Gastric cancer	No	No	PD
209	Botensilimab Monotherapy: 1.0 mg/kg Q6W	Mesothelio ma	Yes	No	SD
210	Botensilimab 2.0 mg/kg Q6W + Balstilimab 3.0 mg/kg Q2W	Testicular cancer	No	No	PD
211	Botensilimab Monotherapy: 0.1 mg/kg Q3W	Uveal melanoma	Yes	No	SD

3 Subjects with best overall response (BOR) of complete response (CR), partial response (PR) or
4 stable disease (SD). Best overall response is the best response recorded over all on-study time-
5 point assessments recorded before start of a new anti-cancer therapy.